Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Other (Income) Expense Breakdown by Year
Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M) ($M)
Merck Other (Income) Expense Breakdown: -$368M in FY2025, up 2,528.6% from a year earlier.
Latest, FY2025
-368
Period ended Dec 31, 2025
Change on a year earlier
+2,528.6%
-14 in FY2024
History
6 years
Since FY2018
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| Loss (income) from investments in equity securities, net (1) | 196 | 156 | (368 | ) | (14 | )”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 4.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other (Income) Expense Breakdown — (Income) Loss on Equity Securities, Net ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -368 | +2,528.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -14 | -95.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | -340 | -124.0% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 1,419 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2019 | Dec 31, 2019 | -170 | -47.5% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | -324 | – | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
Cite this data
StockData. (2026). Merck Other (Income) Expense Breakdown ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/other-inc-exp-eq-sec
See every metric in the Merck KPI table. Data updated Oct 26, 2026.